Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer
- 1 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 16 (10), 1966-1972
- https://doi.org/10.1158/1055-9965.epi-07-0302
Abstract
Objective: We analyzed the association of 54 biomarkers from seven classes including adipokines, immune response metalloproteinases, adhesion molecules, and growth factors with prostate cancer risk adjusting for the Prostate Cancer Prevention Trial (PCPT) risk score. Methods: A total of 123 incident prostate cancer cases and 127 age-matched controls were selected from subjects in the San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. Prediagnostic serum concentrations were measured in the sample collected at baseline using LabMAP technology. The odds ratios (OR) of prostate cancer risk associated with serum concentrations of 54 markers were estimated using univariate conditional logistic regression before and after adjustment for the PCPT risk score. Two-way hierarchical unsupervised clustering techniques were used to evaluate whether the 54-marker panel distinguished cases from controls. Results: Vascular endothelial growth factor, resistin, interleukin 1Ra (IL-1Ra), granulocyte colony-stimulating factor, matrix metalloproteinase-3, plasminogen activator inhibitor, and kallikrein-8 were statistically significantly (P < 0.05) underexpressed in prostate cancer cases, and α-fetoprotein was statistically significantly overexpressed in prostate cancer cases, but all had area underneath the receiver-operating characteristic curve P < 0.0008) or after adjustment for the PCPT risk score. Statistical clustering of patients by the marker panel did not distinguish a separate group of cases from controls. Conclusions: This age-matched case-control study did not support findings of increased diagnostic potential from a 54-marker panel when compared with the conventional risk factors incorporated in the PCPT risk calculator. Future discovery of new biomarkers should always be tested and compared against conventional risk factors before applying them in clinical practice. (Cancer Epidemiol Biomarkers Prev 2007;16(10):1966–72)Keywords
This publication has 18 references indexed in Scilit:
- External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationUrology, 2006
- Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialJNCI Journal of the National Cancer Institute, 2006
- Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian CancerClinical Cancer Research, 2006
- Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Expression of interleukin‐8 gene in radical prostatectomy specimens is associated with advanced pathologic stageThe Prostate, 2005
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical ProstatectomyJournal of Clinical Oncology, 2004
- Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cellsJournal of Cellular Physiology, 2002
- Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 With Prostate Cancer Invasion, Progression, and MetastasisJournal of Clinical Oncology, 2002
- Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent StudyJournal of Clinical Endocrinology & Metabolism, 2001